Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6011.5000 -59.50 (-0.98%)
NSE Jan 23, 2026 15:31 PM
Volume: 460.5K
 

6011.50
-0.98%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 6% YoY to | 1038 crore (I-direct estimate: | 957 crore) driven by growth across segments EBITDA margins declined 724 bps YoY to 31.4% (I-direct estimate: 36%), impacted mainly by lower gross margins (60.7% in Q3FY18 vs. 64.1% in Q3FY17), higher remediation cost & forex loss of | 16 crore in Q3FY18 vs. gain of | 0.7 crore in Q3FY17. Subsequently, EBITDA declined 14% YoY to | 326 crore (I-direct estimates of | 345 crore)...
Divi's Laboratories .. has an average target of 6270.00 from 6 brokers.
More from Divi's Laboratories Ltd.
Recommended